CRY2 and breast carcinoma: A systematical analysis of genomic profiling and clinical data showed significantly decreased Cry1 and Cry2 mRNA levels in multiple cancer types, including breast carcinoma, lung squamous cell carcinoma, thyroid carcinoma, and lung adenocarcinoma [13].